Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.

Inclusion Criteria: * Agree with all study procedures, sign and date back by their own free will, the IC; * Be between 18 and 50 years, of both sexes; * Present a body mass index (BMI) greater than or equal to 20 and less than or equal to 28; * are considered healthy, clinical, psychological and laboratory; * are female, but they have and maintain a safe method of contraception during the study. Exclusion Criteria: * Known hypersensitivity to filgrastim; * Hypersensitivity to products derived from E. coli; * fever or infectious disease in the 07 days preceding the first administration; * Positive serology for hepatitis B or C and HIV; * Prior treatment with CSFs, interleukins and interferons; * Participation in a clinical study in the last 12 months; * Donation or loss of blood in the 03 months preceding the study; * General anesthesia in the 03 months preceding the study; * Provide a history of alcohol abuse, drug or drugs; * Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological, psoriasis, gout, acute myocardial infarction, thyroid or psychiatric disease; * Pregnant or lactating women.